DUPIXENT is the first and only biologic treatment for patients aged 12 years and older with uncontrolled moderate-to-severe atopic dermatitis to target IL-4 and IL-13 receptor signaling, a source of Type 2 inflammation.1,2
When topical prescription therapies are not enough, consider DUPIXENT to help your
appropriate patients who are struggling to control their disease.2,3
Image of an actual patient with atopic dermatitis. Not a clinical trial patient.